Effects of fluoxetine on the polysomnogram in outpatients with major depression

Neuropsychopharmacology

Volumn 20, Issue 5, 1999, Pages 447-459

  Trivedi, Madhukar H ^a   Rush, A John ^a   Armitage, Roseanne ^a   Gullion, Christina M ^a   Grannemann, Bruce D ^a   Orsulak, Paul J ^a   Roffwarg, Howard P ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Fluoxetine; REM sleep; Sleep EEG

Indexed keywords

FLUOXETINE;

ADULT; AGED; ANIMAL CELL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OUTPATIENT; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REM SLEEP; SLEEP DISORDER; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; POLYSOMNOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; SLEEP STAGES; SLEEP, REM; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033136172     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00131-6     Document Type: Article

References (36)

1. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised. Washington, DC, American Psychiatric Press.
2. Armitage R., Hoffmann R., Loewy D., Moffitt A. Variations in period-analyzed EEG asymmetry in REM and NREM sleep. Psychophysiology. 26:1989;329-336.
3. Armitage R., Rush A.J., Trivedi M., Cain J., Roffwarg H.P. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology. 10:1994;123-127.
4. Armitage R., Trivedi M., Rush A.J. Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology. 12:1995;159-165.
5. Ciapparelli A., Dani A., Figura A., Gemignani A., Guazzelli M. The effects of fluoxetine (FL) on sleep pattern. A clinical and all-night EEG study in patients with major depression J Sleep Res. 1:1992;41.
6. Depression Guideline Panel (1993): Clinical Practice Guideline. Depression in Primary Care: Volume 2: Treatment of Major Depression. (AHCPR Publication No. 93-0551.) Rockville, MD, U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.
7. Dorsey C.M., Lukas S.E., Cunningham S.L. Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacology. 14:1996;437-442.
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
9. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 6:1967;278-296.
10. Heiligenstein J.H., Faries D.E., Rush A.J., Andersen J.S., Pande A.C., Roffwarg H.P., Dunner D., Gillin J.C., James S.P., Lahmeyer H., Zajecka J., Tollefson G.D., Gardner D.M. Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. Psychiatry Res. 52:1994;327-339.
11. Hendrickse W.A., Roffwarg H.P., Granneman B.D., Orsulak P.J., Armitage R., Cain J.W., Battaglia J., Debus J., Rush A.J. The effects of fluoxetine on the polysomnogram of depressed outpatients. A pilot study Neuropsychopharmacology. 10:1994;85-91.
12. López-Ibor J.J. Jr. The involvement of serotonin in psychiatric disorders and behavior. Br J Psychiatry. 153(suppl 3):1988;26-39.
13. Luebke J.I., Greene R.W., Semba K., Kamondi A., McCarley R.W., Reinder P.B. Serotonin hyperpolarizes cholinergic low-threshold burst neurons in the rat laterodorsal tegmental nucleus in vitro. Proc Natl Acad Sci USA. 89:1992;743-747.
14. Keck P.E. Jr., Hudson J.I., Dorsey C.M., Campbell P.I. Effect of fluoxetine on sleep. Biol Psychiatry. 29:1991;618-619.
15. Kupfer D.J., Spiker D.G., Coble P.A., Neil J.F., Ulrich R., Shaw D.H. Sleep and treatment prediction in endogenous depression. Am J Psychiatry. 138:1981;429-434.
16. McCarley R.W. REM sleep and depression. Common neurobiological control mechanisms Am J Psychiatry. 139:1982;565-570.
17. Meltzer H.Y., Lowy M.T. The serotonin hypothesis of depression. Meltzer H.Y. Psychopharmacology. The Third Generation of Progress:1987;513-526 Raven Press, New York.
18. Mitani A., Ito K., Hallanger A.E., Wainer B.H., Kataoka K., McCarley R.W. Cholinergic projections from the laterodorsal and pedunculopontine tegmental nuclei to the pontine giganticellular tegmental field in the cat. Brain Res. 451:1988;397-402.
19. Nicholson A.N., Pascoe P.A. Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacology. 27:1988;597-602.
20. Nofzinger E.A., Reynolds C.F. III, Thase M.E., Frank E., Jennings J.R., Fasiczka A.L., Sullivan L.R., Kupfer D.J. REM sleep enhancement by bupropion in depressed men. Am J Psychiatry. 152:1995;274-276.
21. Nunez P. Electrical Fields of the Brain. 1981;Oxford Universities Press, New York.
22. Orsulak P.J., Kenney J.T., Debus J.R., Crowley G., Wittman P.D. Determination of the antidepressant fluoxetine and its metabolite in serum by reverse-phase HPLC, with ultraviolet detection. Clin Chem. 34:1988;1875-1878.
23. Rechtschaffen A., Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. 1968;National Institute of Health, Washington, DC. (NIH Publ No. 204). US Government Printing Office.
24. Reynolds C.F. III, Kupfer D.J. Sleep research in affective illness. State-of-the-art circa. 1987.(Sleep 10):1987;199-215.
25. Rush A.J., Cain J.W., Raese J., Stewart R.S., Waller D.A., Debus J.R. Neurobiological bases for psychiatric disorders. Rosenberg R.N. Comprehensive Neurology. 1991;555-608 Raven Press, New York.
26. Rush A.J., Giles D.E., Jarrett R.J., Fedlman-Koffler F., Debus J.R., Weissenberger J.E., Orsulak P.J., Roffwarg H.P. Reduced REM latency predicts response to tricyclic medication in depressed outpatients. Biol Psychiatry. 26:1989;61-72.
27. Rush A.J., Giles D.E., Schlesser M.A., Fulton C.L., Weissenburger J.E., Burns C.T. The Inventory for Depressive Symptomatology (IDS). Psychiatry Res. 18:1986;65-87.
28. Rush A.J., Gullion C.M., Basco M.R., Jarrett R.B., Trivedi M.H. The inventory of depressive symptomatology (IDS). Psychometric properties Psychol Med. 26:1996;477-486.
29. Saletu B., Frey R., Krupka M., Anderer P., Grunberger J., See W.R. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep. 14:1991;439-447.
30. Schenck C.S., Mahowald M.W., Kim S.W., O'Connor K.A., Hurwitz T.D. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep. 15:1992;226-235.
31. Shiromani P.J., Armstrong D.M., Berkowitz A., Jeste D.V., Gillin J.C. Distribution of choline acetyltransferase immunoreacive somata in the feline brainstem. Implications for REM sleep generation Sleep. 11:1988;1-16.
32. Siegel J.M. Mechanisms of sleep control. J Clin Neurophysiol. 7:1990;49-65.
33. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III-R (SCID) I. History, rationale, and description Arch Gen Psychiatry. 49:1992;624-629.
34. van Bemmel A.L., van den Hoofdakker R.H., Beersma D.G.M., Bouhuys A.L. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology. 113:1993;225-230.
35. von Bardeleben U., Steiger A., Gerken A., Holsboer F. Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls. Int Clin Psychopharmacol. 4(Suppl 1):1989;1-5.
36. Vogel G.W., Buffenstein A., Minter K., Hennessey A. Drug effects on REM sleep and on endogenous depression. Neurosci Biobehav Rev. 14:1990;49-63.